FDA Lifts Clinical Hold on Tenaya's TN-201 Gene Therapy for Genetic Heart Disease
核心洞察
The FDA has removed the clinical hold on Tenaya Therapeutics' MyPEAK-1 Phase 1b/2a trial of TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (搜索).
TN-201 is an AAV9-based gene therapy designed to address the underlying genetic cause of HCM by delivering a functional MYBPC3 (搜索) gene via single intravenous infusion.
The trial targets approximately 120,000 patients in the US with MYBPC3 (搜索)-associated HCM, representing 20% of the overall HCM population.
Tenaya Therapeutics announced on December 11, 2025, that the U.S. Food and Drug Administration has officially lifted the clinical hold on its MyPEAK-1 Phase 1b/2a clinical trial of TN-201 gene therapy. The experimental treatment targets MYBPC3-associated hypertrophic cardiomyopathy (搜索) (HCM), a severe genetic heart condition affecting approximately 120,000 patients in the United States.
The clinical hold removal comes after Tenaya addressed all FDA concerns related to the trial. The company is now implementing protocol amendments in collaboration with clinical sites before resuming patient dosing. These changes standardize practices for patient monitoring and management of the immunosuppressive regimen used in the trial.
Gene Therapy Approach for Genetic Heart Disease
TN-201 represents an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to address the root cause of MYBPC3 (搜索)-associated HCM. The treatment delivers a functional MYBPC3 gene to heart muscle cells through a single intravenous infusion, aiming to increase insufficient myosin-binding protein C (MyBP-C (搜索)) levels and potentially halt or reverse disease progression.
Variants in the MYBPC3 (搜索) gene constitute the most common genetic cause of hypertrophic cardiomyopathy (搜索), accounting for approximately 20% of the overall HCM population. MYBPC3-associated HCM is a severe and progressive condition affecting patients across all age groups, from infants to adults. Mutations in this gene result in insufficient expression of MyBP-C (搜索) protein, which is essential for regulating heart contraction.
The disease manifests as a hypercontractile heart with left ventricular thickening, leading to symptoms including chest pain, shortness of breath, palpitations, and fainting. Patients with MYBPC3 (搜索) mutations face higher risks of earlier disease onset and serious outcomes, including heart failure (搜索) symptoms, arrhythmias, stroke, and sudden cardiac arrest or death.
Trial Design and Safety Profile
The MyPEAK-1 Phase 1b/2a clinical trial is a multi-center, open-label, dose-escalating study evaluating symptomatic adults diagnosed with MYBPC3 (搜索)-associated HCM. The trial is designed to assess safety, tolerability, and clinical efficacy of a one-time intravenous infusion of TN-201.
The study has tested doses of 3E13 vg/kg and 6E13 vg/kg in two cohorts of three patients each and is enrolling additional MYBPC3 (搜索)-positive adults with either nonobstructive or obstructive forms of HCM in dose expansion cohorts. To date, TN-201 has been generally well tolerated, and the trial's data and safety monitoring board endorsed continued enrollment following a comprehensive safety review this summer.
The protocol amendments formalize learnings from the timing and dosing of immunosuppressive agents, which enabled shorter durations and lower cumulative doses of these medications between cohorts despite higher TN-201 doses. The immunosuppression regimen of prophylactic prednisone and sirolimus remains unchanged.
Regulatory Recognition and Development Timeline
TN-201 has received significant regulatory recognition, including Fast Track, Orphan Drug, and Rare Pediatric Drug Designations from the FDA. The therapy has also received orphan medicinal product designation from the European Commission.
Recent trial data from Cohort 1 patients at 52 weeks or more of follow-up and available data for Cohort 2 patients at 12 and 26 weeks were featured in a late-breaker presentation at the American Heart Association Scientific Sessions with simultaneous publication in Cardiovascular Research.
Tenaya expects the clinical hold will not impact data milestones or development timelines. The company currently has no approved therapeutics that address the underlying genetic cause of HCM, representing a significant unmet medical need in this patient population.
Broader Pipeline Context
Tenaya Therapeutics operates as a clinical-stage biotechnology company focused on discovering, developing, and delivering potentially curative therapies for heart disease. Beyond TN-201, the company's pipeline includes TN-401, a gene therapy for PKP2 (搜索)-associated arrhythmogenic right ventricular cardiomyopathy (搜索), and TN-301, a clinical-stage small molecule HDAC6 inhibitor for potential heart failure (搜索) treatment.